SCHEMBL24298133

SCHEMBL24298133

Cc1cccc(C)c1-c1cc(Oc2cccc(N)c2)nc(NS(=O)(=O)c2cccc(N)c2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ TSHR P16473 2/20 0.45
▸ POLB P06746 2/20 0.42
▸ PIK3C2B O00750 1/20 0.42
▸ PIK3C2G O75747 1/20 0.42
▸ FFAR4 Q5NUL3 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ MAPT P10636 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ PGR P06401 1/20 0.40
▸ F2 P00734 1/20 0.39
▸ PRSS1 P07477 1/20 0.39
▸ PRSS2 P07478 1/20 0.39
▸ PRSS3 P35030 1/20 0.39
▸ PLAU P00749 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29457761 1.00 SMN1; SMN2 (0.45) SMN1; SMN2TSHRPOLBPIK3C2BPIK3C2G
SCHEMBL26807086 0.95 TSHR (0.49) SMN1; SMN2TSHRPOLBPIK3C2BPIK3C2G
SCHEMBL29567420 0.86 SMN1; SMN2 (0.57) SMN1; SMN2TSHRFFAR4ALDH1A1CYP3A4
SCHEMBL24310003 0.86 SMN1; SMN2 (0.57) SMN1; SMN2TSHRFFAR4ALDH1A1CYP3A4
SCHEMBL24309603 0.86 POLB (0.45) SMN1; SMN2TSHRPOLBPIK3C2BPIK3C2G
SCHEMBL24309585 0.86 NR3C1 (0.41) SMN1; SMN2TSHRPOLBFFAR4ALDH1A1
SCHEMBL29567101 0.86 NR3C1 (0.41) SMN1; SMN2TSHRPOLBFFAR4ALDH1A1
SCHEMBL29702841 0.85 ACLY (0.40) SMN1; SMN2TSHRPOLBLMNA
SCHEMBL24330886 0.85 ACLY (0.40) SMN1; SMN2TSHRPOLBLMNA
SCHEMBL29702851 0.85 SMN1; SMN2 (0.38) SMN1; SMN2TSHRPOLBALDH1A1F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382924-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
US-20230382924-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
WO-2022076621-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382924-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B SMN1; SMN2 4840/4885TSHR 1941/4885POLB 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback